SCHEMBL4079930

SCHEMBL4079930

N#Cc1ccc2c(c1)c(-c1ccc3ncccc3c1)nn2C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
KDR P35968 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
MTOR P42345 1/20 0.42
PIK3CG P48736 1/20 0.42
EPHB4 P54760 1/20 0.42
PRKDC P78527 1/20 0.42
KDM1A O60341 3/20 0.40
ADORA2A P29274 3/20 0.40
TGFBR1 P36897 3/20 0.38
ATR Q13535 2/20 0.37
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
MET P08581 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378043 0.88 RXRA (0.38) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL4089123 0.83 KCNH2 (0.37) ABL1SRCPRKDCKDM1AATR
SCHEMBL4080192 0.83 RXRA (0.39) ABL1ATRRXRARXRBRXRG
SCHEMBL4080434 0.83 RXRA (0.37) ABL1ATRRXRARXRBRXRG
SCHEMBL4083268 0.83 RXRA (0.37) ABL1ATRRXRARXRBRXRG
SCHEMBL5378035 0.82 CYP11B2 (0.45) KDM1AATR
SCHEMBL5375543 0.82 ATR (0.39) KDM1AATRRXRARXRBRXRG
SCHEMBL4047351 0.82 CYP4F2 (0.40) PRKDCKDM1ANPC1RAB9A
SCHEMBL5377790 0.81 ARF6 (0.38) ATRRXRARXRBRXRG
SCHEMBL4094652 0.81 RAB9A (0.37) SRCPRKDCKDM1AATRRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 PIK3CD 940/4885ABL1 1387/4885EGFR 836/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 PIK3CD 1037/4885ABL1 1282/4885EGFR 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.